biorchestra

"RNA Technology Will Open the Way for Alzheimer's Treatment"

14 January 2020

Enter 09/25/2019 17:22  modified 9.26.2019 01:22


Inhibition of microRNA in the brain
reduces inflammation and activates immune cell function


“Using the principle of action of microribonucleic acid (RNA) provides the answer to Alzheimer's dementia, an incurable disease.”Ryu Jin-hyeob, CEO of Biorchestra, said.

Alzheimer's dementia is one of the most common incurable diseases. Currently available treatments are focused on alleviating or delaying symptoms. Alzheimer's dementia is known to involve a toxic protein called amyloid beta. However, it is not known exactly how this material causes Alzheimer's. Global pharmaceutical bio companies such as Pfizer, Johnson & Johnson, Eli Lilly, Roche and Biogen have failed to develop dementia treatments.

Discover new ways to treat dementia

Biorchestra is studying immune cells and microRNAs in the brain that eliminate amyloid beta. When amyloid beta is produced, the immune cells eat it. Excessive amyloid beta decreases the macrophages of immune cells and releases inflammatory substances during this process. Inflammatory substances destroy brain neurons (neurons). The more garbage there is in the alleys, the more the trucks load, which reduces cleaning efficiency and produces soot.

Ryu found that inhibiting certain microRNAs in the brain activates the function of immune cells and reduces inflammatory secretion. A related technology is microRNA interference technology (SiRNA). The company's new drug candidate, 'BMD-001', has a multi-mechanism that activates immune cells and suppresses inflammatory responses through the blood brain barrier (BBB) ​​through its own drug delivery system. It is currently in preclinical stage in Korea. The company plans to enter the first global clinical phase in 2021 after undergoing a global preclinical within this year.

Determination of founding to realize research results

Ryu earned his Ph.D. in Pathology and Immunology from the University of Tokyo, Japan. His focus was on protein degradation. Proteolysis is associated with Alzheimer's dementia, which has naturally attracted interest. If you try to get rid of amyloid beta protein after a nerve cell injury, you're already late. The idea of ​​developing a new drug using RNA was then obtained.

Mr. Ryu said, “We looked at the global academic trends one year before the start of business and collected the funds after the start-up. Biorchestras of

interest from large Korean companies

attracted 20 billion won last month. In addition to venture capital firms such as Daily Partners, Chong Kun Dang Holdings also participated in the investment. Chong Kun Dang Holdings invested 5 billion won as a strategic investor.

Biorchestra also has technology exports in mind. Mr. Ryu said, “We are preparing to secure intellectual property rights by applying for patents to various countries around the world.”

RNA (ribonucleic acid)

Macromolecular compounds involved in protein synthesis, such as deciphering genetic information and carrying amino acids. RNA therapeutics artificially regulate RNA activity to promote or inhibit the expression of certain genes.


By Park Sang-ik, staff reporter dirn@hankyung.com


Ⓒ Hankyung.com, All Rights Reserved

기사 원문보기

news